CELL AND GENE THERAPY FOR ONCOLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The global cell and gene therapy for oncology market is estimated to be valued at USD 8,641.9 Mn in 2026 and is expected to reach USD 138,425.0 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 44.7% from 2026 to 2033. The market for global cell and gene therapy for oncology is among the fastest-growing markets in the field of oncology therapeutics due to the growing number of cancers and the increasing need for personalized and targeted therapeutic solutions. The major firms engaged in this field are striving to develop state-of-the-art treatments such as CAR-T, TCR, and genetically engineered immunotherapy that provide better results than existing therapies.

The technological progress in gene editing, development of viral vectors, and cell engineering technologies is revolutionizing the cancer therapy process. There are several other factors contributing to the market's growth such as increased participation in clinical trials, approvals, and financial investments by biopharmaceutical companies. Moreover, rising use of precision medicine, improvements in production, and strategic partnerships are driving innovation in the cell and gene-based cancer treatment market.

Market Dynamics

The global cell and gene therapy for oncology market is spurred by an increasing burden of cancer across the globe and an increasing demand for oncology treatments that offer greater precision. Increased public awareness about new cancer therapies, coupled with advances made in techniques like CAR-T cell therapy, gene-editing, and viral vectors, is further boosting the growth of the market. Moreover, an increased number of clinical trials and investment in innovative oncology treatments by major players in biopharmaceuticals can be seen.

Some of the factors restricting the growth of the market include the high costs associated with oncology cell and gene therapy, the high costs of production, and stringent regulatory frameworks for the same. Safety issues related to the adverse side effects of such procedures, such as cytokine release syndrome, also present themselves. Nevertheless, there are ample opportunities for growth within the market, owing to the rise of allogenic and off-the-shelf therapies, wider applications for solid tumors, and increased investments in manufacturing facilities.

Key Features of the Study

• This report provides in-depth analysis of the global cell and gene therapy for oncology market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cell and gene therapy for oncology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study Gilead Sciences, Novartis AG, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, bluebird bio, CRISPR Therapeutics, Allogene Therapeutics, Iovance Biotherapeutics, and Adaptimmune Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cell and gene therapy for oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy for oncology market

Market Segmentation

• Therapy Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Cell Therapy
    • Stem Cell Therapy
    • T-Cell Therapy
    • Mesenchymal Stem Cell (MSC) Therapy
    • Others
  • Gene Therapy
    • Gene Induced Immunotherapy
    • Oncolytic Virotherapy
    • Therapy Gene Transfer
• Technology Insights (Revenue, USD Mn, 2021 - 2033)
  • Cell Therapy Technology
    • Autologous
    • Allogeneic
    • Xenogeneic
  • Gene Therapy Technology
    • Viral Vector-Based Gene Therapy
    • Non-Viral Vector-Based Gene Therapy
• Indication Insights (Revenue, USD Mn, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Leukaemia and Lymphoma
  • Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals and Cancer Treatment Centers
  • Research and Academic Institutes
  • Biotechnology and Pharmaceutical Companies
  • Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Gilead Sciences
  • Novartis AG
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Legend Biotech
  • bluebird bio
  • CRISPR Therapeutics
  • Allogene Therapeutics
  • Iovance Biotherapeutics
  • Adaptimmune Therapeutics